Dr. Gregory Frost, Chairman & CEO of EXUMA Biotechnology, shares his insights into the tremendous progress made in developing autologous CAR-T therapies, as well as the challenges that remain for cell therapies surrounding safety and accessibility with Karen Jagoda on the Empowered Patient Podcast. EXUMA’s own “rPOC” (meaning “rapid point of care”) platform has the potential to dramatically reduce the cost of CAR-T production for both liquid and solid tumors. A recent round of funding is also supporting the development of EXUMA’s logic-gated CAR-T technology, a technology which may help avoid potential on-target, off-tumor toxicity in solid tumor malignancies, such as gastric, breast and ovarian cancers.
